VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 41 filers reported holding VERONA PHARMA PLC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,393 | -14.4% | 3,337 | +11.0% | 0.00% | – |
| Q2 2023 | $63,525 | -41.8% | 3,005 | -44.7% | 0.00% | – |
| Q1 2023 | $109,075 | +0.1% | 5,432 | +30.3% | 0.00% | – |
| Q4 2022 | $108,936 | +1261.7% | 4,169 | +435.9% | 0.00% | – |
| Q3 2022 | $8,000 | +166.7% | 778 | +18.8% | 0.00% | – |
| Q1 2022 | $3,000 | -40.0% | 655 | -25.5% | 0.00% | – |
| Q3 2021 | $5,000 | -58.3% | 879 | -37.5% | 0.00% | – |
| Q1 2021 | $12,000 | 0.0% | 1,407 | -18.3% | 0.00% | – |
| Q4 2020 | $12,000 | +33.3% | 1,723 | +23.4% | 0.00% | – |
| Q3 2020 | $9,000 | -43.8% | 1,396 | -65.1% | 0.00% | – |
| Q1 2020 | $16,000 | -72.4% | 4,000 | -60.2% | 0.00% | – |
| Q4 2019 | $58,000 | +1060.0% | 10,055 | +801.8% | 0.00% | – |
| Q3 2019 | $5,000 | -28.6% | 1,115 | -19.6% | 0.00% | – |
| Q2 2019 | $7,000 | +600.0% | 1,387 | +905.1% | 0.00% | – |
| Q4 2018 | $1,000 | -92.9% | 138 | -80.4% | 0.00% | – |
| Q1 2018 | $14,000 | – | 703 | +70200.0% | 0.00% | – |
| Q4 2017 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |